Avtor/Urednik		Uršič, Katja; Kos, Špela; Kamenšek, Urška; Čemažar, Maja; Ščančar, Janez; Buček, Simon; Kranjc, Simona; Starešinič, Barbara; Serša, Gregor
Naslov		Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma
Tip		članek
Vol. in št.		, št. Vol. 119
Leto izdaje		2018
Obseg		str. 161-171
ISSN		1567-5394 - Bioelectrochemistry (Amsterdam, Netherlands)
Jezik		eng
Abstrakt		Interest in platinum-based chemotherapeutics such as oxaliplatin (OXA) and cisplatin (CDDP) has been reinvigorated by their newly described impacts on tumor-specific immune responses. In addition to CDDP, OXA is frequently used to treat cancers. Based on the characteristics of OXA, which are similar to those of CDDP, and the presumably more pronounced immunomodulatory effect of OXA, OXA is a candidate for electrochemotherapy (ECT). We compared the effectiveness of intratumoral ECT with OXA to that of ECT with CDDP in murine B16F10 melanoma to determine the equieffective dose. Special attention was given to the elicitation of immunogenic cell death and local immune response. Based on the in vitro and in vivo results pertaining to effectiveness and drug uptake in cells and tumors, ECT with OXA is as effective as ECT with CDDP when the OXA dose is increased 1.6-fold. Exposure of melanoma cells to ECT induces immunogenic cell death when either OXA or CDDP is used, which correlates with a comparable increase in lymphocyte infiltration into tumors after ECT with either OXA or CDDP. Based on these results, OXA is a valid platinum-based drug for use with ECT, and the effectiveness of ECT with OXA is comparable to that of the well-established ECT with CDDP. Furthermore, both drugs display equal and specific immune responses following ECT.
Proste vsebinske oznake		elektrokemoterapija cisplatin oxaliplatin melanom imunogena celična smrt imunski odgovor electrochemotherapy melanoma immunogenic cell death immune response oxaliplatin cisplatin